1.Turner RC, Holman RR, Cull CA, et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (United Kingdom Prospective Diabetes Study 33). Lancet. 1998;352:837-853.
2.
2.Hanson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principle results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762.
3.
3.American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2001;24(Suppl 1):S33-S43.
4.
4.Carretero OA, Oparil S.Essential hypertension. Part II: Treatment. Circulation. 2000;1O1:446-453.
5.
5.Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498-511.
6.
6.Abramowicz MA, Zucotti G, Rizack MA, et al. Choice of lipid-regulating drugs. Med Lett Drugs Ther. 2001;43:43-48.
7.
7.Malhotra HS, Goa KL. Atorvastatin: An updated review of its pharmacological properties and use in dyslipidaemia. Drugs. 2001;61:1835-1881.
8.
8.Hansen HP, Jensen BR, Gaede PH, et al. Lack of impact of low-dose acetylsalicylic acid on kidney function in type 1 diabetic patients with microalbuminuria. Diabetes Care. 2000;23:1742-1745.
